Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

What it owns vs. what it owes Q2 FY2026, 30 June 2026

Liabilities are $29.6M more than assets: shareholders’ equity is negative. What is a balance sheet?

30 June 2026 · total $101.1M

Owns

$4.3MLong-term assets
$5.5MOther short-term assets
$91.3MCash & short-term investments

Funded by

$130.7MOther liabilities

Debt is 0.0% of the total; liabilities are $29.6M more than assets.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
133.42 99.07 101.36 96.83
Total non-current assets
3.59 20.52 8.27 4.25
Total Assets
137.01 119.59 109.63 101.08
Total current liabilities
35.97 29.24 28.11 36.04
Total non-current liabilities
105.04 107.36 112.29 94.66
Total liabilities
141.01 136.60 140.40 130.70
Common Equity (Total)
(3.99) (17.01) (30.77) (29.62)
Shareholders Equity (Total)
(3.99) (17.00) (30.77) (29.62)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026